2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106832
    Vatanidipine 116308-55-5 98%
    Vatanidipine (Watanidipine) is an orally active dihydropyridine (DHP)-type calcium channel blocker and a useful antihypertensive agent. Vatanidipine shows vasodilatory effects and also suppresses noradrenaline release from sympathetic nerve endings.
    Vatanidipine
  • HY-106855
    Almokalant 123955-10-2 98%
    Almokalant is a class III antiarrhythmic agent, acts as a potassium channel blocker, and inhibits a specific component (Ikr) of the time-dependent delayed rectifier K+ current.
    Almokalant
  • HY-106861
    NIP-121 135244-62-1 98%
    NIP-121 is a new type of potassium channel opener. NIP-121 significantly reduces mean pulmonary artery pressure and total pulmonary resistance through vasodilation. NIP-121 can be used for research on pulmonary arterial hypertension.
    NIP-121
  • HY-106865
    Mivazerol 125472-02-8 98%
    Mivazerol is a selective α2-adrenoceptor agonist. Mivazerol has an anti-ischemic activity. Mivazerol decreases the spontaneous release of serotonin (5-HT) and significantly inhibits the immobilization stress-induced enhancement of norepinephrine (NE), dopamine (DA) and dihydroxyphenylacetic acid (DOPAC). Mivazerol can be used for myocardial ischemia research.
    Mivazerol
  • HY-106895
    L-702958 136081-07-7 98%
    L-702958 is a potent hERG blocker (IC50 = 14.3 nM). L-702958 can be used for research on arrhythmia.
    L-702958
  • HY-106899
    MK 287 135947-75-0 98%
    MK 287 is a potent, selective and orally active antagonist of platelet-activating factor receptor (PAFR). MK 287 can inhibit [3H]C18-PAF binding to human platelet, polymorphonuclear leukocyte (PMN) and lung membranes with K1 values of 6.1, 3.2, and 5.49 nM, respectively. MK 287 can inhibit PAF-induced aggregation of platelets in plasma or gel-filtered platelets and elastase release from PMNs with ED50 values of 56, 1.5 and 4.4 nM. MK 287 can be used for the research of cardiovascular disease, such as thrombosis.
    MK 287
  • HY-106902
    F-1394 162490-89-3 98%
    F-1394 is an orally active acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor that inhibits dietary cholesterol absorption in mice. F-1394 can be used in cardiovascular disease research.
    F-1394
  • HY-106904
    Nexopamil 136033-49-3 98%
    Nexopamil is a calcium antagonist of Ca2+ channel, 5HT2, 5HT1A, 5HT1C and dopamine D2 receptors. Nexopamil exhibits vasodilatory, cardioprotective, and platelet aggregation inhibiting effects. Nexopamil can be used for researches of stable or unstable angina and possibly of peripheral arterial occlusive disease.
    Nexopamil
  • HY-106914
    Sinitrodil 143248-63-9 98%
    Sinitrodil (ITF 296) is an orally active organic nitrate with anti-ischaemic effect. Sinitrodil can be used for acute and chronic heart diseases research.
    Sinitrodil
  • HY-106916
    Unoprostone 120373-36-6 99.0%
    Unoprostone, a prostaglandin F2α analog, is a large conductance Ca2+-activated K+ (BK) channels and ClC-2 type chloride channels activator. Unoprostone reduces oxidative stress- and light-induced retinal cell death, and phagocytotic dysfunction. Unoprostone reduces intraocular pressure and can be used for the study of glaucoma, ocular hypertension and retinitis pigmentosa.
    Unoprostone
  • HY-106932
    L-734217 146144-48-1 98%
    L-734217 is an orally active and potent fibrinogen receptor antagonist and an antithrombotic agent. L-734217 is excreted largely by the renal route and partly into the bile in dogs. L-734217 is promising for research of thrombotic disorders.
    L-734217
  • HY-106938
    Eldacimibe 141993-70-6 98%
    Eldacimibe is an ACAT2 inhibitor. Eldacimibe can lower plasma cholesterol levels by blocking cholesterol absorption and can prevent macrophages from turning into foam cells. Eldacimibe can be used in the study of cardiovascular diseases (atherosclerosis), endocrine and metabolic diseases (hypercholesterolemia) .
    Eldacimibe
  • HY-106973
    Nolomirole 90060-42-7 98%
    Nolomirole (CHF 1035) is an orally active and selective DA2 dopaminergic receptor/α2-adrenoceptor agonist. Nolomirole attenuates the heart failure signs in the Monocrotaline (HY-N0750)-induced congestive heart failure model. Nolomirole increases cardiac output.
    Nolomirole
  • HY-106975
    SCH-42354 144505-58-8 98%
    SCH-42354 is a potent, orally active neutral endopeptidase (NEP) inhibitor, is the pharmacologically active form of the proagent SCH-42495. SCH-42354 inhibits the hydrolysis of NEP to enhance the activity of atrial natriuretic peptide (ANP). SCH-42354 inhibits hydrolysis of leu-enkephalin and ANF with IC50 values of 8.3 nM and 10.0 nM, respectively. SCH-42354 has antihypertensive activity.
    SCH-42354
  • HY-106987
    SP/W 5186 139146-65-9 98%
    SP/W-5186 is a nitric oxide (NO) donor agent containing a cysteine structure. SP/W-5186 can improve cardiac function, reduce myocardial damage, protect vascular endothelial function and inhibit inflammation and oxidative stress. SP/W-5186 has the ability to inhibit oxidative damage induced by peroxynitrite (ONOO⁻). SP/W-5186 can be used in the research of myocardial ischemia-reperfusion injury.
    SP/W 5186
  • HY-107000
    RIG 200 202656-49-3 98%
    RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003)-induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on coronary artery bypass grafting.
    RIG 200
  • HY-107010
    Esprolol 396654-09-4 98%
    Esprolol is an orally active and potent β-adrenergic receptor antagonist. Esprolol is rapidly metabolized by blood and tissue esterases to form the active metabolite amoxolol. Esprolol holds potential for research in exercise-induced angina.
    Esprolol
  • HY-107023
    AZD 9684 775274-06-1 98%
    AZD 9684 is a carboxypeptidase U inhibitor,and can be used for study of thrombus.
    AZD 9684
  • HY-107037
    Tolmesoxide 38452-29-8 98%
    Tolmesoxide (RX71107) is a peripheral vascular dilator with blood pressure lowering activity. Tolmesoxide has shown direct vasodilation in the human forearm arterial bed and dorsal hand vein. Tolmesoxide can dose-dependently increase blood flow in the forearm and produce dilation during contraction of the dorsal hand veins. Tolmesoxide can be used to study high blood pressure and angina.
    Tolmesoxide
  • HY-107054
    ESP-31015 413624-55-2 98%
    ESP-31015 (ETC-1001) is an orally active and non-fibrate based PPARα agonists. ESP-31015 demonstrates significant lipid-regulating effects in the obese Zucker rat model. ESP-31015 can be used in cardiovascular disease research.
    ESP-31015
Cat. No. Product Name / Synonyms Application Reactivity